Viridian Therapeutics, Inc. . Full-time Employee Directory
Biotechnology ResearchMassachusetts, United States201-500 Employees
Viridian Therapeutics, Inc. is a biotechnology research company based in Waltham, Massachusetts. It focuses on engineering and developing medicines for patients with serious and rare diseases, leveraging antibody discovery and protein engineering to create differentiated therapies for validated targets in established disease areas. The company is advancing a thyroid eye disease (TED) program with multiple candidates in the clinic, including VRDN-001 in two global Phase 3 trials, and envisions VRDN-003 as a follow-on subcutaneous therapy. In addition to TED, Viridian is pursuing neonatal Fc receptor inhibitors, VRDN-006 and VRDN-008, with potential applications across autoimmune diseases. Beyond its TED portfolio, the company is developing an anti-TSHR program for TED or Graves disease. Viridian operates in the biotechnology research sector and has engaged in collaborations to advance its programs; a notable development in 2026 was a manufacturing partnership with WuXi Biologics.